Expression of c-kit in fibroepithelial lesions of the breast is a mast cell phenomenon

Modern Pathology

Volumn 21, Issue 10, 2008, Pages 1238-1245

  Djordjevic, Bojana ^a   Hanna, Wedad M ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

c kit; CD117; Fibroadenoma; Fibroepithelial lesion; Mast cell; Phyllodes

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; STEM CELL FACTOR RECEPTOR; TOLONIUM CHLORIDE; TRYPTASE;

ARTICLE; BREAST FIBROADENOMA; CONTROLLED STUDY; CYSTOSARCOMA PHYLLOIDES; EPITHELIUM; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAST CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTO ONCOGENE; STAINING;

BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FIBROADENOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MAST CELLS; MASTECTOMY; PHYLLODES TUMOR; PROTO-ONCOGENE PROTEINS C-KIT; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 52549093194     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.78     Document Type: Article

References (33)

1. Bellocq J, Magro G. Pathology and Genetics of Tumors of the Breast and Female Genital Organs, 1st edn. IARCPress: Lyon, 2003, pp432.
2. Yared MA, Middleton LP, Meric F, et al. Expression of c-kit proto-oncogene product in breast tissue. Breast J 2004;10:323-327.
3. Sawyer EJ, Poulsom R, Hunt FT, et al. Malignant phyllodes tumours show stromal overexpression of cmyc and c-kit. J Pathol 2003;200:59-64.
4. Tornillo L, Terracciano LM. An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 2006;59:557-563.
5. Allander SV, Nupponen NN, Ringner M, et al. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res 2001;61:8624-8628.
6. Andersson J, Sjogren H, Meis-Kindblom JM, et al. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002;160:15-22.
7. Wang WL, Healy ME, Sattler M, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000;19:3521-3528.
8. Krystal GW, Honsawek S, Litz J, et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000;6:3319-3326.
9. O'Dwyer ME, Druker BJ. Chronic myelogenous leukaemia-new therapeutic principles. J Intern Med 2001;250:3-9.
10. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
11. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001;20:5054-5058.
12. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003;39:2006-2011.
13. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004;28:889-894.
14. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710.
15. Carvalho S, e Silva AO, Milanezi F, et al. c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations? J Clin Pathol 2004;57:1075-1079.
16. Chen CM, Chen CJ, Chang CL, et al. CD34, CD117, and actin expression in phyllodes tumor of the breast. J Surg Res 2000;94:84-91.
17. Esposito NN, Mohan D, Brufsky A, et al. Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med 2006;130:1516-1521.
18. Tan PH, Jayabaskar T, Yip G, et al. p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study. Mod Pathol 2005;18:1527-1534.
19. Tse GM, Putti TC, Lui PC, et al. Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. Mod Pathol 2004;17:827-831.
20. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 1998;29:498-504.
21. Dabiri S, Huntsman D, Makretsov N, et al. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol 2004;17:690-695.
22. Hongxin F, Gulley ML. Molecular Pathology Protocols, 1st edn. Humana Press Inc: Totowa, NJ, 2001, pp1-3.
23. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791-795.
24. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-8121.
25. Lasota J, Jasinski M, Sarlomo-Rikala M, et al. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999;154:53-60.
26. Lasota J, Wozniak A, Sarlomo-Rikala M, et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000;157:1091-1095.
27. Baek JY, Tefferi A, Pardanani A, et al. Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease. Leuk Res 2002;26:83-90.
28. Hussain MA, Tyagi SP, Tyagi N, et al. Stromal cellular response in breast tumours and allied lesions. J Indian Med Assoc 1992;90:119-121.
29. Amini RM, Aaltonen K, Nevanlinna H, et al. Mast cells and eosinophils in invasive breast carcinoma. BMC Cancer 2007;7:165.
30. Cabanillas-Saez A, Schalper JA, Nicovani SM, et al. Characterization of mast cells according to their content of tryptase and chymase in normal and neoplastic human uterine cervix. Int J Gynecol Cancer 2002;12:92-98.
31. Aoki M, Pawankar R, Niimi Y, et al. Mast cells in basal cell carcinoma express VEGF, IL-8 and RANTES. Int Arch Allergy Immunol 2003;130:216-223.
32. Shunyakov L, Ryan CK, Sahasrabudhe DM, et al. The influence of host response on colorectal cancer prognosis. Clin Colorectal Cancer 2004;4:38-45.
33. Junankar SR, Eichten A, Kramer A, et al. Analysis of immune cell infiltrates during squamous carcinoma development. J Investig Dermatol Symp Proc 2006;11:36-43.